GlassScriptPhysician profile
David R Allen
NPI 1952371163
$3,741.87
in general payments reported to CMS, 2019-2025
40 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $517 · 2021: $538 · 2022: $293 · 2023: $412 · 2024: $759 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $577.61 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $469.82 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $329.04 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $274.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.61 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.26 | 2020-2025 | Xifaxan |
| Amgen INC. | $144.71 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $137.81 | 2019-2025 | Trintellix, Eohilia |
| Sunovion Pharmaceuticals INC. | $129.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $123.04 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $111.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.81 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $96.46 | 2019-2025 | Hetlioz, Fanapt |
| Pfizer INC. | $92.50 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $80.18 | 2019-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.